- Home
- ANL vs SCLX Comparison
ANL vs SCLX Comparison
Compare ANL & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- SCLX
- Stock Information
- Founded
- ANL 2004
- SCLX 2011
- Country
- ANL Cayman Islands
- SCLX United States
- Employees
- ANL 127
- SCLX 113
- Industry
- ANL
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- SCLX Health Care
- Exchange
- ANL Nasdaq
- SCLX Nasdaq
- Market Cap
- ANL 115.1M
- SCLX 81.7M
- IPO Year
- ANL 2023
- SCLX N/A
- Fundamental
- Price
- ANL $3.12
- SCLX $0.61
- Analyst Decision
- ANL Strong Buy
- SCLX Strong Buy
- Analyst Count
- ANL 2
- SCLX 3
- Target Price
- ANL $9.00
- SCLX $11.33
- AVG Volume (30 Days)
- ANL 29.1K
- SCLX 184.3K
- Earning Date
- ANL 08-08-2024
- SCLX 11-26-2024
- Dividend Yield
- ANL N/A
- SCLX N/A
- EPS Growth
- ANL N/A
- SCLX N/A
- EPS
- ANL N/A
- SCLX N/A
- Revenue
- ANL $5,000,000.00
- SCLX $50,833,000.00
- Revenue This Year
- ANL N/A
- SCLX $32.77
- Revenue Next Year
- ANL N/A
- SCLX $50.71
- P/E Ratio
- ANL N/A
- SCLX N/A
- Revenue Growth
- ANL N/A
- SCLX 9.41
- 52 Week Low
- ANL $1.85
- SCLX $0.54
- 52 Week High
- ANL $17.48
- SCLX $2.63
- Technical
- Relative Strength Index (RSI)
- ANL 64.09
- SCLX 28.71
- Support Level
- ANL $2.88
- SCLX $0.73
- Resistance Level
- ANL $3.50
- SCLX $1.14
- Average True Range (ATR)
- ANL 0.41
- SCLX 0.11
- MACD
- ANL 0.12
- SCLX -0.04
- Stochastic Oscillator
- ANL 60.19
- SCLX 11.99
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.